{
    "nct_id": "NCT06617546",
    "official_title": "A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study to Assess Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of FTX-101 After Subcutaneous Injection of FTX-101 in Healthy Male Subjects",
    "inclusion_criteria": "* Willingness to comply with all study procedures and availability for the duration of the study\n* Healthy adult male\n* Aged at least 18 years but not older than 59 years\n* Body mass index (BMI) within 18.5 kg/m^2 to 32.0 kg/m^2, inclusively\n* Non- or ex-smoker\n* Have no clinically significant diseases captured in the medical history or evidence of clinically significant findings on the physical examination (including vital signs) and/or ECG.\n\nKey\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years\nMust have maximum age of 59 Years",
    "exclusion_criteria": "* Supine or semi-supine pulse rate less than 45 beats per minute (bpm) or more than 100 bpm\n* Supine or semi-supine blood pressure below 90/50 mmHg\n* Supine or semi-supine blood pressure higher than 150/95 mmHg\n* History of significant hypersensitivity to FTX-101 or any related products (including excipients of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs\n* Presence or history of significant gastrointestinal, liver or kidney disease, or surgery that may affect drug bioavailability\n* History of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic or dermatologic disease\n* Showing suicidal tendency from 6 months prior to screening\n* Presence of out-of-range cardiac intervals at screening defined as:\n\n  * PR < 110 msec, PR > 200 msec\n  * QRS < 60 msec, QRS >110 msec)\n  * QT Interval Corrected for Heart Rate using Fridericia's Correction Formula (QTcF): â€¢ > 450 msec\n  * History of additional risk factors for torsade's de pointes\n  * Use of concomitant medications that prolong the QT/ corrected QT (QTc) interval\n* Current use (in the last 6 months) of alcohol (> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic)\n* Any history of substance or alcohol use disorder within the past 2 years and/or current maintenance therapy (within the past 2 years) for treatment of substance use disorder\n* Use of any prescription drugs in the 28 days or 5 half-lives, whichever is longer, prior to the first study treatment administration, that in the opinion of an investigator would put into question the status of the participant as healthy\n* Use of St. John's wort in the 28 days prior to the first study treatment administration\n* Positive screening results to HIV Ag/Ab combo, hepatitis B surface Ag or hepatitis C virus tests\n* Intake of an investigational product (IP) in the 28 days prior to the first study treatment administration or within 5 times the elimination half-life of the IP, whichever is longer\n* Donation of plasma in the 7 days prior to the first study treatment administration\n* Donation of 1 unit of blood to American Red Cross or equivalent organization or donation of over 500 mL of blood in the 56 days prior to the first study treatment administration",
    "miscellaneous_criteria": "Key"
}